A rally in the shares stalled around $180 in December and early January.
These stocks are displaying bearish tendencies based on their technical patterns.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
We have two price target areas for this biopharmaceutical firm.
Let's check the charts on this clinical stage drug developer.
Let's check the charts and indicators.
Wednesday morning will bring traders, investors, Romans, and countrymen more macroeconomic results than they could ever wanted to peruse at one time.
Here's what the charts show.
Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
The company reported earnings and the shares have rolled over and turned down.